Consensus LivaNova PLC

Stocks

LIVN

GB00BYMT0J19

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 16:00:00 2026-08-18 EDT			5-day change	1st Jan Change
79.86 ^USD	-1.99%		+1.63%	+29.79%

08-05	LivaNova PLC, Q2 2026 Earnings Call, Aug 05, 2026
08-05	LivaNova PLC Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Evolution of the Average Target: LivaNova PLC

Evolution of the Target Price: LivaNova PLC

Changes in Analyst Recommendations: LivaNova PLC

29fd77696134ff1b26b96f9f58f1.-5OQGYR5Q1A0jzRRHoQinqx9zlznvpKBUWskg9J3ixI.tf_pfskWIjZg9ltmX-V3zuIVghfV7cTqAyR1yOAlymOe8flV1D9wB0LQWw~3328a6d5f25131948180bbf822d0981d

Analysts' recommendations: LivaNova PLC

02-25	Needham Adjusts Price Target on LivaNova to $81 From $64	MT
12-19	KeyBanc Initiates LivaNova at Overweight With $81 Price Target	MT
25-10-01	LivaNova Shares Fall After Goldman Sachs Downgrade	MT
25-10-01	Goldman Sachs Downgrades LivaNova to Neutral From Buy, Trims Price Target to $55 From $56	MT
25-08-06	LivaNova beats estimates for Q2 revenue, raises FY guidance	RE
25-05-20	Wolfe Upgrades LivaNova to Outperform From Peer Perform, Price Target is $60	MT
25-02-26	Wolfe Research Downgrades LivaNova to Peer Perform From Outperform	MT
24-09-17	Baird Upgrades LivaNova to Outperform From Neutral	MT
24-07-31	Needham Raises LivaNova's Price Target to $75 From $72, Buy Rating Maintained	MT
24-02-27	Barclays Adjusts Price Target on LivaNova to $61 From $57, Keeps Equalweight Rating	MT
24-02-26	Barclays Raises Price Target on LivaNova to $61 From $57, Maintains Equalweight Rating	MT
24-02-22	Baird Adjusts LivaNova's Price Target to $62 From $56, Keeps Neutral Rating	MT
24-02-22	Wolfe Research Adjusts LivaNova's Price Target to $65 From $58, Keeps Outperform Rating	MT
24-02-22	Mizuho Securities Adjusts Price Target on LivaNova to $75 From $70, Maintains Buy Rating	MT
24-02-21	Needham Adjusts Price Target on LivaNova to $72 From $62, Keeps Buy Rating	MT
24-02-20	Mizuho Securities Upgrades LivaNova to Buy From Neutral, Raises Price Target to $70 From $60	MT
23-10-23	Needham Adjusts LivaNova Price Target to $62 From $71, Maintains Buy Rating	MT
23-09-06	HSBC Initiates LivaNova With Hold Rating, Price Target is $52	MT
23-05-08	Barclays Adjusts Price Target on LivaNova to $51 From $45, Maintains Equalweight Rating	MT
23-05-03	Needham Adjusts LivaNova's Price Target to $63 From $77, Keeps Buy Rating	MT
23-04-14	Mizuho Initiates LivaNova at Neutral With $48 Price Target	MT
22-12-21	Barclays Initiates Coverage on LivaNova With Equal Weight Rating, $62 Price Target	MT
22-11-23	Goldman Sachs Adjusts LivaNova's Price Target to $63 From $73, Keeps Buy Rating	MT
22-11-03	Needham Adjusts Price Target on LivaNova to $77 From $88, Maintains Buy Rating	MT
22-08-16	Goldman Sachs Cuts Price Target on LivaNova to $73 From $85, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	LIVANOVA PLC					+11.95%
	ABBOTT LABORATORIES					+5.96%
	MEDTRONIC PLC					+6.9%
	CENCORA, INC.					+17.86%
	HOYA CORPORATION					+16.22%
	BECTON, DICKINSON AND COMPANY					+7.55%
	DEXCOM, INC.					+5.04%
	MEDLINE INC.					+30.76%
	WEST PHARMACEUTICAL SERVICES, INC.					+16.78%
	TERUMO CORPORATION					+20.64%
	Average					+13.96%
	Weighted average by Cap.					+10.71%